• About us
• Contact

Advertisement

Organisation › Details

Topas Therapeutics GmbH

Topas is an early stage therapeutics company using ground breaking nanoparticle technology to target autoimmune and inflammatory diseases via the induction of antigen specific immune tolerance in the liver. The platform has been exclusively licensed from the University Medical Center Hamburg-Eppendorf (“UKE”) where it was invented by Johannes Herkel, Jörg Heeren and other colleagues in Hamburg. It is anticipated that Topas will advance their initial program targeting multiple sclerosis into clinical development in 2017. *

 

	Start	2015-10-13 renamed
	Predecessor	NanoDeLiver GmbH
	Industry	Topas Particle Conjugates technology platform
	Industry 2	TPM203 (Topas Pharmaceuticals)
	Person	Martin, Klaus (Topas Therapeutics 202008– CEO before Apobiologix + Polpharma Biologics + Sandoz Biopharmaceuticals)
	Person 2	Greiner, Erich F. (Cedrus Therapeutics 201704 before Evotec 200604)
	Region	Hamburg
	Country	Germany
	Street	88 Falkenried Haus B
	City	20251 Hamburg
	Tel	+49-40-56081-467
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2024-12-29

Advertisement

More documents for Topas Therapeutics GmbH

• [1] Topas Therapeutics GmbH. (5/6/24). "Press Release: Topas Therapeutics Appoints Hugo Fry as CEO". Hamburg....
• [2] Topas Therapeutics GmbH. (7/29/21). "Press Release: Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round". Hamburg....
• [3] Topas Therapeutics GmbH. (10/19/20). "Press Release: Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing". Hamburg....
• [4] Topas Therapeutics GmbH. (10/19/20). "Press Release: Topas Therapeutics Appoints Klaus Martin, Ph.D. as Chief Executive Officer". Hamburg....
• [5] Vico Therapeutics B.V.. (10/1/20). "Press Release: Dutch Vico Therapeutics Strengthens Leadership Team with the Appointment of Rupert Sandbrink as Chief Medical Officer and Anders Hinsby as Independent Director". Leiden....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.